ClinicalTrials.gg
CompletedNCT04539938HER2CLIMB-04Updated Mar 23, 2026Results posted

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

A Phase 2 interventional study of tucatinib and trastuzumab deruxtecan in HER2 Positive Breast Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Completed at 140 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing tucatinib in Breast Neoplasms — 7 open to participants now, 19 under way, 3 of them phase 3. tucatinib · Breast Neoplasms.

Enrollment
9th of 31
70 · median 41
Started
2020
with 2 others
Phase 2
16 of 31
6 open now
Registered
12th of 31
by date
Lead sponsor
4 of 31
Seagen, a wholly owned subsidiary of Pfizer

Among the 31 studies testing tucatinib in Breast Neoplasms, this one is the 9th largest by enrollment, is one of 3 that started in 2020, is one of 16 in phase 2, and was the 12th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 31 studies testing tucatinib in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tucatinib

tucatinib: first FDA approval 2020 (TUKYSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing tucatinib in Breast Neoplasms, or all of them as a file.
02

Study summary

This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer.

Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and T-DXd.

03

Conditions studied

  • HER2 Positive Breast Cancer

Browse trials for

Keywords

  • HER2+ breast cancer
  • Metastatic breast cancer
  • Stage IV breast cancer
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have confirmed + breast cancer, as defined by the current American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines, previously determined at a Clinical Laboratory Improvements Amendments (CLIA)-certified or International Organization for Standardization (ISO)-accredited laboratory.
  • History of prior treatment with a taxane and trastuzumab in the LA/M setting OR progressed within 6 months after or adjuvant treatment, including a taxane and trastuzumab.
  • Have progression of unresectable LA/M breast cancer after last systemic therapy (as confirmed by investigator), or be intolerant of last systemic therapy
  • Have assessable by v1.1
  • Have Performance Status (ECOG PS) 0 or 1
  • Have a of at least 6 months, in the opinion of the investigator
  • CNS Inclusion - Based on medical history and screening contrast brain magnetic resonance imaging (MRI), participants with a history of must have one of the following:

    • Untreated brain metastases not needing immediate local therapy. For participants with untreated central nervous system (CNS) lesions >2.0 cm on screening contrast brain MRI, discussion with and approval from the medical monitor is required prior to enrollment
    • Previously treated brain metastases

      • Brain metastases previously treated with local therapy may either be stable since treatment or may have progressed since prior local CNS therapy, provided that there is no clinical indication for immediate re-treatment with local therapy in the opinion of the investigator
      • Participants treated with CNS local therapy for newly identified or previously treated progressing lesions found on contrast brain MRI performed during screening for this study may be eligible to enroll if all of the following criteria are met:

        • Time since whole brain radiation therapy (WBRT) is ≥14 days prior to first dose of study treatment, time since stereotactic radiosurgery (SRS) is ≥7 days prior to first dose of study treatment, or time since surgical resection is ≥28 days
        • Other sites of measurable disease by RECIST v1.1 are present
      • Relevant records of any CNS treatment must be available

Exclusion criteria

Exclusion Criteria

  • Have previously been treated with:

    • Lapatinib or neratinib within 12 months of starting study treatment (except in cases where lapatinib or neratinib was given for ≤21 days and was discontinued for reasons other than disease progression or severe toxicity)
    • Tucatinib or enrolled on a tucatinib clinical trial
    • Any /epidermal growth factor receptor (EGFR) or HER2 tyrosine kinase inhibitor (TKI) (eg, afatinib) at any time previously
    • Trastuzumab deruxtecan or another antibody-drug conjugate (ADC) consisting of an exatecan derivative
  • Have received treatment with:

    • Any systemic anti-cancer therapy (including hormonal therapy) or experimental agent ≤21 days of first dose of study treatment or are currently participating in another interventional clinical trial. An exception for the of hormonal therapies is gonadotropin releasing hormone (GnRH) agonists used for ovarian suppression in premenopausal women, which are permitted concomitant medications
    • Treatment with non-CNS radiation ≤7 days prior to first dose of study treatment
    • Major surgery \<28 days of first dose of study treatment
  • Have cardiopulmonary disease (such as history of iterstitial lung disease (ILD)/pneumonitis that required systemic , or have current ILD/pneumonitis, or where suspected ILD /pneumonitis cannot be ruled out be imaging at screening)
  • Have known myocardial infarction or unstable angina within 6 months prior to first dose of study treatment
  • Known to be positive for by surface antigen expression. Known to be positive for infection. Participants who have been treated for hepatitis C infection are permitted if they have documented sustained virologic response of 12 weeks
  • Presence of known chronic liver disease
  • Active or uncontrolled clinically serious infection
  • Have inability to swallow pills or significant gastrointestinal disease which would preclude the adequate oral absorption of medications
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Single Arm

    Tucatinib + trastuzumab deruxtecan

    Drug: tucatinib · Drug: trastuzumab deruxtecan

Interventions

  • 300 mg orally twice daily

    Also known as: TUKYSA, ARRY-380, ONT-380, PF-07265792

  • 5.4 mg/kg via intravenous (into the vein; IV) infusion on Day 1 of each of 21-day cycle

    Also known as: T-DXd, Enhertu, DS-8201

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 According to Investigator (INV) Assessment

    Confirmed objective response rate was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per investigator according to RECIST v1.1. For a response to be considered confirmed, the subsequent response had to be at least 4 weeks after the initial response. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). PR: a greater than equal to (\>=) 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. 95% exact confidence interval (CI) was based on Clopper-Pearson method.

    Time frame: From the first dose of study treatment until the first documented PD or before start of any new anti-cancer therapy (up to 43 months)

Secondary outcomes

  1. Progression-Free Survival (PFS) Per RECIST v1.1 According to INV

    PFS as per INV was defined as the time from the start of the study treatment to the first documentation of PD per RECIST v1.1 or death due to any cause, whichever occurred first. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. Kaplan-Meier methods was used for analysis.

    Time frame: From the start of study treatment until the first documentation of PD or death due to any cause, whichever occurred first (approximately 46.2 months of treatment exposure)

  2. Duration of Response (DOR) Per RECIST v1.1 According to INV

    DOR was defined as the time from the date of first documented objective response (CR or PR that was subsequently confirmed) to the date of first documented PD per RECIST v1.1 or death due to any cause, whichever occurred first. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: a \>= 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Kaplan-Meier methods was used for analysis.

    Time frame: From the first documented objective response until the first documentation of PD or death, whichever occurred first (approximately 46.2 months)

  3. Disease Control Rate (DCR) Per RECIST v1.1

    DCR was defined as percentage of participants with confirmed CR, PR or stable disease (\[SD\] or non-CR/non-PD) per RECIST v1.1. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: a \>= 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. 95% CI was computed using Clopper-Pearson method.

    Time frame: From first dose of study treatment until PD or death, whichever occurred first (approximately 46.2 months)

  4. Overall Survival (OS)

    OS was defined as the time from the start of study treatment to the date of death due to any cause. Participants who were not known to have died at the end of study follow-up, observation of OS was censored on the date the participant was last known to be alive (i.e., the date of last contact). For participants without data beyond the day of treatment initiation, OS was censored on the date of treatment initiation. Kaplan-Meier methods was used for analysis.

    Time frame: From date of start of study treatment until date of death or censoring date (approximately 46.2 months)

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigational participant administered a medicinal product which did not necessarily have a causal relationship with this treatment. AEs included all non-serious adverse events (non-SAEs) and SAEs. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib or trastuzumab deruxtecan) and up through 30 days after the last dose of study treatment.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)

  6. Number of Participants With Serious Adverse Events (SAEs)

    An SAE was an AE that at any dose, met any of the following criteria: resulted in death, was life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or disability (substantial disruption of the participant's ability to conduct normal life functions), congenital anomaly/birth defect or considered medically significant.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)

  7. Number of Participants With Treatment Emergent Adverse Events Based on Severity

    An AE was defined was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib or trastuzumab deruxtecan) and up through 30 days after the last dose of study treatment. AEs were graded based on National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 where, grade 1= mild; grade 2= moderate; grade 3= severe; grade 4= life-threatening; grade 5= death.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)

  8. Number of Participants With Treatment Related TEAEs

    An AE was defined was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib or trastuzumab deruxtecan) and up through 30 days after the last dose of study treatment. Relatedness of AEs to study treatment was determined by the investigator.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)

  9. Number of Participants With Treatment Emergent Clinical Laboratory Abnormalities

    Laboratory abnormalities included: hematology; hemoglobin increased and decreased, leukocytes decreased, lymphocytes increased and decreased, neutrophils decreased and platelets decreased. Chemistry: alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatinine, magnesium, potassium, sodium and total bilirubin increased and glucose, magnesium, potassium and sodium decreased. Treatment-emergent laboratory abnormalities were defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. Laboratory test results were graded according to NCI CTCAE version 4.03, where Grade 0: no AE, Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Number of participants with any grade are reported in this outcome measure.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)

  10. Number of Participants With TEAEs Leading to Dose Modification

    An AE was defined was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib or trastuzumab deruxtecan) and up through 30 days after the last dose of study treatment. Dose modification included dose reduction, dose delay, dose hold and dose interruption. Number of participants with TEAEs leading to any type of dose modification for tucatinib and T-DXd are reported in this outcome measure.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)

  11. Number of Participants With TEAEs Leading to Treatment Discontinuation

    An AE was defined was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib or trastuzumab deruxtecan) and up through 30 days after the last dose of study treatment. In this outcome measure, participants with TEAEs leading to discontinuation of tucatinib and T-DXd treatment is reported.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)

  12. Number of Participants According to Change From Baseline Categories in Ejection Fraction

    Cardiac ejection fraction was assessed using multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO). Baseline was defined as most recent non-missing assessment on or before first dose date. Number of participants according to change from baseline in ejection fraction categories (i.e., no decrease, decrease \<10%, decrease 10-\<20% and decrease \>=20%) is reported in this outcome measure.

    Time frame: Baseline up to 30 days after last dose of study treatment (approximately 47.2 months)

  13. Number of Participants With Clinically Significant Vital Signs

    Vital signs included body temperature, respiratory rate, heart rate, oxygen saturation, and systolic blood pressure (SBP) and diastolic blood pressure (DBP). The clinically significant vital signs were defined as: heart rate \> 100 beats per minute (bpm), temperature \>=38.0 degrees Celsius (C), respiratory rate \> 20 breaths per minute and oxygen saturation \< 88%; SBP \>=120 millimeters of mercury (mmHg) or DBP \>=80 mmHg; SBP \>=140 mmHg or DBP \>=90 mmHg and SBP \>=160 mmHg or DBP\>=100 mmHg.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)

07

Results

Posted Jul 31, 2025

Participant flow

Participants diagnosed with unresectable locally advanced or metastatic (LA/M) human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC) with or without brain metastases, who received prior treatment with a taxane and trastuzumab or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including a taxane and trastuzumab (with or without pertuzumab) were enrolled at 24 sites in the United States.

Participant flow — Overall Study
MilestoneTotal Participants
Started70
Completed0
Not completed70
Withdrew: Death36
Withdrew: Withdrawal by subject4
Withdrew: Sites terminated22
Withdrew: Continued to ltep8

Outcome measures

PrimaryConfirmed Objective Response Rate (cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 According to Investigator (INV) Assessment

Confirmed objective response rate was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per investigator according to RECIST v1.1. For a response to be considered confirmed, the subsequent response had to be at least 4 weeks after the initial response. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). PR: a greater than equal to (\>=) 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. 95% exact confidence interval (CI) was based on Clopper-Pearson method.

Time frame:
From the first dose of study treatment until the first documented PD or before start of any new anti-cancer therapy (up to 43 months)
Reported as:
Number · Percentage of participants
Confirmed Objective Response Rate (cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 According to Investigator (INV) Assessment
Percentage of participantsTotal Participants
Confirmed Objective Response Rate (cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 According to Investigator (INV) Assessment51.4 (39.2 to 63.6)
SecondaryProgression-Free Survival (PFS) Per RECIST v1.1 According to INV

PFS as per INV was defined as the time from the start of the study treatment to the first documentation of PD per RECIST v1.1 or death due to any cause, whichever occurred first. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. Kaplan-Meier methods was used for analysis.

Time frame:
From the start of study treatment until the first documentation of PD or death due to any cause, whichever occurred first (approximately 46.2 months of treatment exposure)
Reported as:
Median · Months
Progression-Free Survival (PFS) Per RECIST v1.1 According to INV
MonthsTotal Participants
Progression-Free Survival (PFS) Per RECIST v1.1 According to INV11.5 (7.5 to 14.1)
SecondaryDuration of Response (DOR) Per RECIST v1.1 According to INV

DOR was defined as the time from the date of first documented objective response (CR or PR that was subsequently confirmed) to the date of first documented PD per RECIST v1.1 or death due to any cause, whichever occurred first. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: a \>= 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Kaplan-Meier methods was used for analysis.

Time frame:
From the first documented objective response until the first documentation of PD or death, whichever occurred first (approximately 46.2 months)
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST v1.1 According to INV
MonthsTotal Participants
Duration of Response (DOR) Per RECIST v1.1 According to INV11.9 (6.0 to NA)
SecondaryDisease Control Rate (DCR) Per RECIST v1.1

DCR was defined as percentage of participants with confirmed CR, PR or stable disease (\[SD\] or non-CR/non-PD) per RECIST v1.1. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: a \>= 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20 % increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. 95% CI was computed using Clopper-Pearson method.

Time frame:
From first dose of study treatment until PD or death, whichever occurred first (approximately 46.2 months)
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Per RECIST v1.1
Percentage of participantsTotal Participants
Disease Control Rate (DCR) Per RECIST v1.194.3 (86.0 to 98.4)
SecondaryOverall Survival (OS)

OS was defined as the time from the start of study treatment to the date of death due to any cause. Participants who were not known to have died at the end of study follow-up, observation of OS was censored on the date the participant was last known to be alive (i.e., the date of last contact). For participants without data beyond the day of treatment initiation, OS was censored on the date of treatment initiation. Kaplan-Meier methods was used for analysis.

Time frame:
From date of start of study treatment until date of death or censoring date (approximately 46.2 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsTotal Participants
Overall Survival (OS)28.4 (20.9 to 36.2)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigational participant administered a medicinal product which did not necessarily have a causal relationship with this treatment. AEs included all non-serious adverse events (non-SAEs) and SAEs. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib or trastuzumab deruxtecan) and up through 30 days after the last dose of study treatment.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsTotal Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)70
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

An SAE was an AE that at any dose, met any of the following criteria: resulted in death, was life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or disability (substantial disruption of the participant's ability to conduct normal life functions), congenital anomaly/birth defect or considered medically significant.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsTotal Participants
Number of Participants With Serious Adverse Events (SAEs)25
SecondaryNumber of Participants With Treatment Emergent Adverse Events Based on Severity

An AE was defined was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib or trastuzumab deruxtecan) and up through 30 days after the last dose of study treatment. AEs were graded based on National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 where, grade 1= mild; grade 2= moderate; grade 3= severe; grade 4= life-threatening; grade 5= death.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events Based on Severity
ParticipantsTotal Participants
Grade 16
Grade 217
Grade 338
Grade 46
Grade 53
SecondaryNumber of Participants With Treatment Related TEAEs

An AE was defined was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib or trastuzumab deruxtecan) and up through 30 days after the last dose of study treatment. Relatedness of AEs to study treatment was determined by the investigator.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Related TEAEs
ParticipantsTotal Participants
Number of Participants With Treatment Related TEAEs67
SecondaryNumber of Participants With Treatment Emergent Clinical Laboratory Abnormalities

Laboratory abnormalities included: hematology; hemoglobin increased and decreased, leukocytes decreased, lymphocytes increased and decreased, neutrophils decreased and platelets decreased. Chemistry: alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatinine, magnesium, potassium, sodium and total bilirubin increased and glucose, magnesium, potassium and sodium decreased. Treatment-emergent laboratory abnormalities were defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. Laboratory test results were graded according to NCI CTCAE version 4.03, where Grade 0: no AE, Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Number of participants with any grade are reported in this outcome measure.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Clinical Laboratory Abnormalities
ParticipantsTotal Participants
Hemoglobin decreased48
Hemoglobin increased1
Leukocytes decreased41
Lymphocytes decreased32
Lymphocytes increased2
Neutrophils decreased34
Platelets decreased21
Alanine Aminotransferase increased35
Alkaline Phosphatase increased28
Aspartate Aminotransferase increased38
Creatinine increased29
Glucose decreased9
Magnesium decreased25
Magnesium increased4
Potassium decreased34
Potassium increased3
Sodium decreased10
Sodium increased12
Total Bilirubin increased16
SecondaryNumber of Participants With TEAEs Leading to Dose Modification

An AE was defined was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib or trastuzumab deruxtecan) and up through 30 days after the last dose of study treatment. Dose modification included dose reduction, dose delay, dose hold and dose interruption. Number of participants with TEAEs leading to any type of dose modification for tucatinib and T-DXd are reported in this outcome measure.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Dose Modification
ParticipantsTotal Participants
TEAEs leading to Tucatinib dose modification47
TEAEs leading to T-DXd dose modification39
SecondaryNumber of Participants With TEAEs Leading to Treatment Discontinuation

An AE was defined was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib or trastuzumab deruxtecan) and up through 30 days after the last dose of study treatment. In this outcome measure, participants with TEAEs leading to discontinuation of tucatinib and T-DXd treatment is reported.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Treatment Discontinuation
ParticipantsTotal Participants
Participants who discontinued tucatinib due to TEAE15
Participants who discontinued T-DXd due to TEAE13
SecondaryNumber of Participants According to Change From Baseline Categories in Ejection Fraction

Cardiac ejection fraction was assessed using multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO). Baseline was defined as most recent non-missing assessment on or before first dose date. Number of participants according to change from baseline in ejection fraction categories (i.e., no decrease, decrease \<10%, decrease 10-\<20% and decrease \>=20%) is reported in this outcome measure.

Time frame:
Baseline up to 30 days after last dose of study treatment (approximately 47.2 months)
Reported as:
Count of participants · Participants
Number of Participants According to Change From Baseline Categories in Ejection Fraction
ParticipantsTotal Participants
No decrease31
Decrease < 10%29
Decrease 10 - < 20%4
Decrease >= 20%0
SecondaryNumber of Participants With Clinically Significant Vital Signs

Vital signs included body temperature, respiratory rate, heart rate, oxygen saturation, and systolic blood pressure (SBP) and diastolic blood pressure (DBP). The clinically significant vital signs were defined as: heart rate \> 100 beats per minute (bpm), temperature \>=38.0 degrees Celsius (C), respiratory rate \> 20 breaths per minute and oxygen saturation \< 88%; SBP \>=120 millimeters of mercury (mmHg) or DBP \>=80 mmHg; SBP \>=140 mmHg or DBP \>=90 mmHg and SBP \>=160 mmHg or DBP\>=100 mmHg.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (approximately 47.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Signs
ParticipantsTotal Participants
Temperature >= 38 degrees C1
SBP >= 120mmHg or DBP >= 80 mmHg66
SBP >= 140 mmHg or DBP >= 90 mmHg39
SBP >= 160 mmHg or DBP >= 100 mmHg7
Respiratory Rate > 20 breaths per minute4
Heart Rate > 100 bpm27
Oxygen Saturation < 88 %1

Adverse events

Collected over From start of study treatment (Day 1) up to 30 days after last dose of study treatment (approximately 47.2 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total Participants39/70 (55.7%)25/70 (35.7%)70/70 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventTotal Participants
PneumoniaInfections and infestations3/70
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders3/70
NauseaGastrointestinal disorders2/70
VomitingGastrointestinal disorders2/70
FatigueGeneral disorders2/70
Febrile neutropeniaBlood and lymphatic system disorders1/70
Ventricular fibrillationCardiac disorders1/70
Abdominal distensionGastrointestinal disorders1/70
Abdominal painGastrointestinal disorders1/70
DiarrhoeaGastrointestinal disorders1/70
Most frequent other events
Showing 10 of 61
Most frequent other events
EventTotal Participants
DiarrhoeaGastrointestinal disorders56/70
NauseaGastrointestinal disorders54/70
FatigueGeneral disorders50/70
VomitingGastrointestinal disorders42/70
ConstipationGastrointestinal disorders38/70
Decreased appetiteMetabolism and nutrition disorders25/70
HeadacheNervous system disorders21/70
HypokalaemiaMetabolism and nutrition disorders20/70
AlopeciaSkin and subcutaneous tissue disorders18/70
Urinary tract infectionInfections and infestations17/70

Baseline characteristics

The all-treated participants analysis set included all participants who received any amount of study drug (tucatinib and/or trastuzumab deruxtecan).

Age, Continuous
Age, Continuous(Years)Total Participants
Mean55.5 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)Total Participants
Female68
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Total Participants
Hispanic or Latino3
Not Hispanic or Latino66
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Total Participants
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American8
White56
More than one race0
Unknown or Not Reported2
Presence or history of treated or untreated brain metastases
Presence or history of treated or untreated brain metastases(Participants)Total Participants
Yes27
No43
HER2 testing results
HER2 testing results(Participants)Total Participants
Immunohistochemistry (IHC) 3 plus (+)41
IHC 2+ and/or Fluorescence in situ hybridization +28
Other1
08

Study locations

140 sites
  • University Of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham, IDS Pharmacy
    Birmingham, Alabama 35249, United States
  • University Of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85704, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85711, United States
  • UCLA Hematology/Oncology - Alhambra
    Alhambra, California 91801, United States
  • UCLA Hematology/Oncology - Burbank
    Burbank, California 91505, United States
  • City of Hope (City of Hope National Medical Center, City of Hope Medical center)
    Duarte, California 91010, United States
  • City of Hope Investigational Drug Services (IDS)
    Duarte, California 91010, United States
  • UCLA Hematology/Oncology - Laguna Hills
    Laguna Hills, California 92653, United States
  • (IRB# 20-001502) Ronald Reagan UCLA Medical Center, Drug Information Center
    Los Angeles, California 90095, United States
  • UCLA Hematology/Oncology
    Los Angeles, California 90095, United States
  • UCLA Hematology/Oncology - Pasadena
    Pasadena, California 91105, United States
  • Zuckerberg San Francisco General Hospital- Breast Clinic
    San Francisco, California 94110, United States
  • Zuckerberg San Francisco General Hospital- Oncology Clinic
    San Francisco, California 94110, United States
  • University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
  • UCLA Hematology/Oncology - San Luis Obispo
    San Luis Obispo, California 93401, United States
  • UCLA Hematology/Oncology - Santa Barbara
    Santa Barbara, California 93105, United States
  • UCLA Hematology/Oncology - Santa Monica
    Santa Monica, California 90404, United States
  • UCLA Hematology/Oncology Parkside
    Santa Monica, California 90404, United States
  • UCLA Hematology/Oncology - Ventura
    Ventura, California 93003, United States
  • UCLA Hematology/Oncology - Westlake
    Westlake Village, California 91361, United States
  • University of Colorado Denver CTO/CTRC - Outpatient.
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
    Aurora, Colorado 80045, United States
  • UC Health Lone Tree Medical Center
    Lone Tree, Colorado 80124, United States
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • Washington Cancer Institute at MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • Florida Cancer Specialists
    Altamonte Springs, Florida 32701, United States
  • Florida Cancer Specialists
    Brandon, Florida 33511, United States
  • Florida Cancer Specialists
    Clearwater, Florida 33761, United States
  • Florida Cancer Specialists
    Gainesville, Florida 32605, United States
  • Florida Cancer Specialists
    Largo, Florida 33770, United States
  • Florida Cancer Specialists
    Lecanto, Florida 34461, United States
  • Florida Cancer Specialists
    Ocala, Florida 34474, United States
  • Florida Cancer Specialists
    Orange City, Florida 32763, United States
  • Florida Cancer Specialists
    Orlando, Florida 32806, United States
  • Florida Cancer Specialists
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists
    Tampa, Florida 33607, United States
  • Florida Cancer Specialists
    Tavares, Florida 32778, United States
  • Florida Cancer Specialists
    The Villages, Florida 32159, United States
  • Florida Cancer Specialists
    Trinity, Florida 34655, United States
  • Florida Cancer Specialists
    Winter Park, Florida 32789, United States
  • Northside Hospital, Inc - GCS/Athens
    Athens, Georgia 30606, United States
  • Winship Cancer Institute @ Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Winship Cancer Institute / Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Atlanta Cancer Care - Atlanta
    Atlanta, Georgia 30342, United States
  • Northside Hospital, Inc. - Central Research Department
    Atlanta, Georgia 30342, United States
  • Northside Hospital, Inc. - GCS/Center Pointe
    Atlanta, Georgia 30342, United States
  • Northside Hospital, Inc - GCS/Blairsville
    Blairsville, Georgia 30512, United States
  • Northside Hospital, Inc - GCS/Canton
    Canton, Georgia 30114, United States
  • Atlanta Cancer Care - Cumming
    Cumming, Georgia 30041, United States
  • Northside Hospital, Inc. - GCS/Decatur
    Decatur, Georgia 30033, United States
  • NHCI Suburban Hematology-oncology Associates - Duluth
    Duluth, Georgia 30096, United States
  • NHCI Suburban Hematology-oncology Associates - lawrenceville
    Lawrenceville, Georgia 30046, United States
  • Northside Hospital, Inc - GCS/Macon
    Macon, Georgia 31217, United States
  • Northside Hospital, Inc. - GCS/Marietta
    Marietta, Georgia 30060, United States
  • Atlanta Cancer Care - Stockbridge
    Stockbridge, Georgia 30281, United States
  • Harry and Jeanette Weinberg Cancer Institute at Franklin Square
    Baltimore, Maryland 21237, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute- Chestnut Hill
    Newton, Massachusetts 02459, United States
  • Mercy Hospital
    Coon Rapids, Minnesota 55433, United States
  • Minnesota Oncology Hematology, PA
    Coon Rapids, Minnesota 55433, United States
  • Mercy Hospital - Unity Campus
    Fridley, Minnesota 55432, United States
  • Minnesota Oncology Hematology, PA
    Fridley, Minnesota 55433, United States
  • Minnesota Oncology Hematology, PA
    Minneapolis, Minnesota 55404, United States
  • Abbott Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
  • Allina Health Cancer institute
    Minneapolis, Minnesota 55407, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Allina Health Cancer Institute
    Saint Paul, Minnesota 55102, United States
  • Minnesota Oncology Hematology PA
    Saint Paul, Minnesota 55102, United States
  • Minnesota Oncology Hematology, PA
    Saint Paul, Minnesota 55102, United States
  • United Hospital
    Saint Paul, Minnesota 55102, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    Omaha, Nebraska 68114, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    Omaha, Nebraska 68124, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    Papillion, Nebraska 68046, United States
  • MSK Basking Ridge
    Basking Ridge, New Jersey 07920, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • MSK Monmouth
    Middletown, New Jersey 07748, United States
  • MSK Bergen
    Montvale, New Jersey 07645, United States
  • MSK Commack
    Commack, New York 11725, United States
  • MSK Westchester
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
    Long Island City, New York 11101, United States
  • Evelyn H. Lauder Breast and Imaging Center (BAIC).
    New York, New York 10065, United States
  • MSK Nassau
    Uniondale, New York 11553, United States
  • Providence Cancer Institute Franz Clinic
    Portland, Oregon 97213, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • UPMC Hillman Cancer Center Passavant North
    Cranberry Township, Pennsylvania 16066, United States
  • UPMC Hillman Cancer Center Erie
    Erie, Pennsylvania 16505, United States
  • UPMC Hillman Cancer Center Mountainview
    Greensburg, Pennsylvania 15601, United States
  • UPMC Hillman Cancer Center UPMC East
    Monroeville, Pennsylvania 15146, United States
  • UPMC Hillman Cancer Center Upper Saint Clair
    Pittsburgh, Pennsylvania 15102, United States
  • Magee-Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • University of Pittsburgh Cancer Institute Investigational Drug Service UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States

Showing the first 100 of 140 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Modi S, Murthy RK, Chien AJ, Lin NU, McAndrew NP, Specht JM, Zelnak AB, Ramos J, Xie D, Ho J, Inoue JK, Carey LA, Hamilton EP. Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study. Clin Breast Cancer. 2026 Jul 10;26(8):21-30. doi: 10.1016/j.clbc.2026.05.010. Online ahead of print. PubMed 42431148 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jul 2024, 43 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 43 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2020
First posted
Sep 7, 2020
StartActual
Dec 1, 2020
Primary completionActual
Jul 15, 2024
CompletionActual
Mar 7, 2025
Results first posted
Jul 31, 2025
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04539938
Responsible party
Sponsor
First posted
Sep 7, 2020
Start date
Dec 1, 2020
Primary completion
Jul 15, 2024
Completion
Mar 7, 2025
Results posted
Jul 31, 2025
Last update
Mar 23, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucatinib · Trastuzumab deruxtecan

Start the discussion